公开(公告)号：US20240043846A1

公开(公告)日：2024-02-08

申请号：US18057050

申请日：2022-11-18

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： HoWon J. Kim ,  In-San Kim ,  Jay S. Kim ,  Sun Hwa Kim ,  Ick Chan Kwon ,  Jong Won Lee ,  Yoo Soo Yang ,  Hong Yeol Yoon

IPC: C12N15/113 ,  A61P35/00

CPC classification number: C12N15/1138 ,  A61P35/00 ,  C12N2310/11 ,  C12N2310/531

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

公开(公告)号：US10213515B2

公开(公告)日：2019-02-26

申请号：US15169493

申请日：2016-05-31

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwangmeyung Kim ,  Ju Hee Ryu ,  Ick Chan Kwon ,  Man Kyu Shim ,  Hong Yeol Yoon

IPC: A61K51/00 ,  A61M36/14 ,  A61K49/00 ,  C07K9/00 ,  G01N33/574 ,  G01N33/58 ,  C07K5/11 ,  C07K5/107 ,  A61K47/54

Abstract: The present disclosure relates to a glycopeptide targeting cancer cells and a contrast agent kit containing the same. The glycopeptide is one wherein an azide reporting monosaccharide is bound to a substrate peptide. As the substrate peptide is specifically cleaved by cathepsin B in cancer cells, an azide reporting monosaccharide is expressed onto the cell surface via metabolic glycoengineering, thereby providing a target for action as a contrast agent. Accordingly, because the azide is exposed to the cell surface only by cathepsin B, as it is specifically expressed in cancer cells, in particular in metastatic cancer cells, while it is limitedly expressed in normal cells and is hardly excreted out the cells, the cancer cells can be selectively imaged by an azide-specific contrast agent.